From insulin to engineered analogues: milestones in peptide medicine

The history of peptide medicine connects molecular identification, manufacturing advances, and clinical evaluation. These achievements reinforce one another, but each answers a different question.

1922: insulin treatment

In 1922, the use of insulin in patients with diabetes marked a decisive therapeutic shift. The work of Banting, Best, Collip, and Macleod combined experimental research, purification, and clinical evaluation. The relationship between these components is particularly important for this article. Detecting activity in an extract did not solve all the problems of its repeated administration. Improving the preparation was part of the breakthrough. When reviewing a new compound, the same conceptual distinction remains. Finding biological activity and having an evaluable intervention are related, but not identical, steps.

A 1922 clinical report by Banting and colleagues described treatment of diabetes with pancreatic extracts (original report, PMC1524425). The broader research-team narrative above is separate from the author list of that particular paper, and this clinical milestone is distinct from later advances in sequencing, synthesis, recombinant production and product authorization.

A defined molecular sequence

Sanger's work on insulin helped establish that a protein could be described by a defined sequence. His 1958 Nobel lecture provides a direct historical source on this journey. The date refers to the lecture and the award, not to a single day of discovery. The conceptual contribution was to move from observed activity to a more precise molecular identity. This allowed for structural comparisons that were previously much more difficult. Characterization provides another kind of evidence. This distinction remains relevant when we evaluate generic names, mixtures, or products whose molecular description is incomplete.

The synthesis of oxytocin

The synthesis of oxytocin constitutes another milestone in the relationship between structure and function. Du Vigneaud described this work in his 1955 Nobel lecture. The chemical production of a peptide hormone demonstrated a different capacity than isolating it from tissues. It also required verifying the identity and properties of the resulting product. We must not present synthesis as an abstract assertion of equivalence without evaluation. The historical lesson is that chemistry made it possible to compare a proposed structure with material produced under controlled conditions. In our classification, this example separates physiological origin from method of manufacture. An endogenous hormone can become the object of synthesis without these two descriptions being contradictory.

Solid-phase synthesis

In 1963, Merrifield published a paper on solid-phase peptide synthesis. The method used a support to facilitate assembly and separation during the process. Its historical significance was expanding the practical possibilities of producing defined sequences. The important thing is to distinguish a manufacturing innovation from a therapeutic demonstration. Being able to synthesize a molecule allows us to investigate it, but it doesn't prove that it treats a disease. In a timeline, these two achievements should occupy different categories. This criterion avoids presenting every technological improvement as if it were already a clinical improvement. Further research is still necessary to connect the resulting product with a specific application.

Recombinant production

In 1979, Goeddel and colleagues published the bacterial expression of synthetic genes for human insulin. This work linked genetic information and the production of peptide components. It represents an experimental milestone in recombinant technology. The date refers to that publication and should not be used as an automatic date of clinical availability. This precision avoids compressing several development steps into a single event. Manufacturing, characterization, and therapeutic use remain distinct dimensions. It does not eliminate the need to evaluate the final product. The useful question is what new capabilities the study provided and what further evidence was needed afterward.

Engineered analogues

Subsequent development incorporated analogues designed to modify pharmacological properties. Semaglutide is one example, related to glucagon-like peptide-1, or GLP-1. The discovery study published in 2015 described modifications aimed at its pharmacological profile. The goal of prolonging exposure should not be confused with a complete demonstration of clinical benefit. These are related questions that require different studies. The story is no longer just about obtaining a hormone, but about designing variants and testing their consequences. When reading a presentation of an analogue, identify whether it describes design intent, experimental properties, or outcomes in patients. This classification prevents the three stages from being combined into a single efficacy claim.

Trials that define clinical benefit

Clinical trials allow for the evaluation of outcomes in defined populations. The STEP 1 trial, published in 2021, evaluated semaglutide in overweight or obese adults without diabetes. The population, the intervention, and the comparison are all part of the conclusion. The historical advance also lies in demanding this degree of precision. A molecule with an interesting mechanism needs interpretable results in patients. When reviewing a therapeutic milestone, ask what outcome was measured and whom it represents. This interpretation is more useful than a timeline that merely lists names and years.

What to remember

Read a therapeutic timeline as a sequence of evidence-generating steps. Discovery, synthesis, a trial publication, and authorization are separate milestones; a date associated with one should not be assigned to another.

Continue with PEPTIDE Academy, Module 1. The complete lessons remain in the Academy; this public article introduces selected concepts.

How we read a new scientific claim

Start with a traceable primary source. Match the title, authors, year and DOI or PMID; an identifier alone is not enough. Then record the study design, population or species, exact intervention, comparator, follow-up and prespecified outcome. Keep an author’s interpretation separate from the observed result.

A conference slide can introduce a question and point to a paper. It cannot replace that paper’s methods or establish that a quoted conclusion applies to another product. A useful reading note has four parts: what was measured, what changed, what can reasonably be inferred and what remains unknown. If the source cannot be matched, mark the claim pending rather than supplying a plausible reference.